Ocular Therapeutix Inc
$ 10.33
-6.43%
05 Mar - close price
- Market Cap 2,403,317,000 USD
- Current Price $ 10.33
- High / Low $ 11.10 / 10.23
- Stock P/E N/A
- Book Value 3.03
- EPS -1.42
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.27 %
- ROE -0.55 %
- 52 Week High 16.44
- 52 Week Low 5.80
About
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company is headquartered in Bedford, Massachusetts.
Analyst Target Price
$26.17
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-05 | 2025-11-04 | 2025-08-05 | 2025-05-05 | 2025-03-10 | 2024-11-05 | 2024-08-07 | 2024-05-07 | 2024-03-11 | 2023-11-07 | 2023-08-07 | 2023-05-08 |
| Reported EPS | -0.29 | -0.38 | -0.39 | -0.3724 | -0.29 | -0.22 | -0.26 | -0.7 | -0.35 | -0.17 | -0.26 | -0.39 |
| Estimated EPS | -0.32 | -0.37 | -0.35 | -0.28 | -0.22 | -0.24 | -0.22 | -0.19 | -0.3 | -0.29 | -0.3 | -0.26 |
| Surprise | 0.03 | -0.01 | -0.04 | -0.0924 | -0.07 | 0.02 | -0.04 | -0.51 | -0.05 | 0.12 | 0.04 | -0.13 |
| Surprise Percentage | 9.375% | -2.7027% | -11.4286% | -33% | -31.8182% | 8.3333% | -18.1818% | -268.4211% | -16.6667% | 41.3793% | 13.3333% | -50% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.3486 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OCUL
2026-03-04 10:52:31
This article provides a comparison of Ocular Therapeutix, Inc. (OCUL) with numerous competitors in the Healthcare Biotechnology sector. It highlights key financial metrics such as market capitalization, current trading prices, P/E ratios, and Return on Equity (ROE) for OCUL and a long list of its peers. The analysis also briefly touches on OCUL's volatility relative to its competitors.
2026-03-03 12:51:47
Ocular Therapeutix Inc. (OCUL) stock surged 22.8% to close at $10.98 following a presentation at the TD Cowen 46th Annual Health Care Conference where management discussed pipeline progress. This jump occurred just days before the company is set to report its fiscal year 2025 earnings on March 6. The company, which focuses on therapies for retinal diseases, holds a net cash position and is advancing several key drugs, with pipeline updates being critical for its valuation.
2026-03-03 07:51:47
Ocular Therapeutix, Inc. (NASDAQ:OCUL) experienced a significant 27.8% increase in short interest during February, reaching 14,706,215 shares, which represents about 6.9% of its shares sold short. This rise occurred alongside insider selling activity, with two key insiders liquidating shares worth over $1.75 million in the last three months. Despite a year-over-year revenue decline and negative margins, analysts maintain a "Moderate Buy" rating with a consensus price target of $23.78.
2026-03-03 03:52:31
Ocular Therapeutix (Nasdaq:OCUL) is a biopharmaceutical company developing therapies for retinal diseases. The stock is considered significantly undervalued based on analyst targets, despite past share dilution and current unprofitability. Key upcoming catalysts include progress with its AXPAXLI program for wet AMD and non-proliferative diabetic retinopathy, which analysts believe will drive future share upside.
2026-03-02 20:52:48
Ocular Therapeutix (NASDAQ:OCUL) saw its shares rise 17.4% on Monday, closing at $10.4990 with 6.29 million shares traded. Analysts maintain a "Moderate Buy" consensus rating with an average target price of $23.78, despite the company reporting mixed fundamentals including an EPS beat but a revenue miss and negative margins. Insider selling has occurred recently, with 197,221 shares sold over the last 90 days.
2026-03-02 15:52:48
Ocular Therapeutix's (OCUL) retina study successfully met its primary endpoint, demonstrating "first-ever superiority" in the field with consistent data and strong disease control. This achievement is expected to lead to a unique superiority label, supporting premium pricing and broad market coverage for diabetic retinal diseases, while also showcasing a favorable safety profile and significant real-world potential.
